Study: Chinese COVID Shot May Offer Elderly Poor Protection
Source: AP News
BUDAPEST, Hungary (AP) — A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.
A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.
This is very, very worrying that these people, who are high-risk, have a poor antibody response,” said Jin Dong-yan, a Hong Kong University virologist who was not affiliated with the study.
Antibody levels are not a direct measure of how protected a person is from COVID-19, but there is growing evidence that they are a good proxy. One expert cautioned that the choice of test kits could have limited the accuracy of the measurements...
Read more: https://apnews.com/article/europe-middle-east-business-science-health-4b770731d5995e3bb49a1d8ec63febbd
- April 1, 2021, general practitioner Gyorgy Teleki vaccinates an elderly patient with the 2nd dose of COVID-19 vaccine produced by Chinese Sinopharm in Taplanszentkereszt, Hungary. A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.
= new reply since forum marked as read
